Timothy Govaerts, MD
Nephrology · Grand Island, NENPI 1780633610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Amgen at 25.0% of the total. That places this record below the midpoint for nephrology clinicians in NE, where the typical reported total is $1,214.
Across 25 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$108
- AstraZeneca$64
- Bayer$55
- Mallinckrodt Hospital Products Inc.$51
- Medtronic$39
- Travere Therapeutics, Inc.$34
- plus $82 from 5 others
What the payments were for
- Food & beverage$432100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $108 |
| AstraZeneca | 4 | $64 |
| Bayer | 3 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| Medtronic | 2 | $39 |
| Travere Therapeutics, Inc. | 2 | $34 |
| Novartis | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Aurinia Pharma U.S., Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
How this compares
$432 in reported general payments places this provider in the 30th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 11 | $36,267 |
| MounjaroTirzepatide | 11 | $18,162 |
| Sevelamer Carbonate | 28 | $4,523 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,279 |
| GengrafCyclosporine, Modified | 11 | $1,358 |
| Gabapentin | 38 | $1,235 |
| Potassium Chloride | 92 | $1,127 |
| Furosemide | 126 | $985 |
| Losartan Potassium | 77 | $953 |
| Metoprolol Succinate | 62 | $837 |
| Calcitriol | 30 | $779 |
| Levothyroxine Sodium | 82 | $747 |
| Atorvastatin Calcium | 72 | $729 |
| Oxycodone Hcl | 17 | $708 |
| Rosuvastatin Calcium | 32 | $618 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Grand Island
- Swathi LavudiGrand Island$1K
- Michael AaronsonLincoln$498K
- Richard LundOmaha$378K
- Jeffrey PasserOmaha$146K
- Rachel BrockLincoln$87K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Prasanth RavipatiOmaha$7K
- Joseph BastOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.